Study of Exchange of Travoprost Intraocular Implant

NCT ID: NCT04615403

Last Updated: 2023-09-26

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

33 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-11-19

Study Completion Date

2022-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study objective is to evaluate the safety of the operative and surgical exchange procedure of Travoprost Intraocular Implant in subjects with open-angle glaucoma or ocular hypertension.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This prospective, non-randomized, open-label, multi-center, single arm, clinical trial intends to implant approximately 45 male and female subjects over 18 years old who have been diagnosed with open-angle glaucoma (OAG) or ocular hypertension (OHT). All subjects are required to meet eligibility criteria at Visit 1 (Screening). The purpose of this study is to evaluate the safety of the implantation and exchange of a Travoprost Intraocular Implant in subjects with open-angle glaucoma or ocular hypertension. Postoperatively, there are 6 follow-up visits over a 12 month period.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Open Angle Glaucoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Implantation and Exchange

Subjects will undergo implantation and exchange of a Travoprost Intraocular Implant through a small temporal clear corneal incision.

Group Type EXPERIMENTAL

Travoprost

Intervention Type DRUG

Implantation and exchange of a Travoprost Intraocular Implant through a clear corneal incision

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Travoprost

Implantation and exchange of a Travoprost Intraocular Implant through a clear corneal incision

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Able and willing to attend scheduled follow-up exams for the duration of the study
* Able and willing to provide written informed consent on the IRB (institutional review board)/IEC (institutional ethics committee)-approved Informed Consent form
* Best spectacle corrected visual acuity of 20/80 or better in each eye.
* Previously qualified for GC-009 clinical trial using the Travoprost Intraocular Implant with the travoprost intraocular implant (G2TR) that is present in the study eye.

Exclusion Criteria

* Glaucoma status as follows:

* Traumatic, uveitic, neovascular, or angle-closure glaucoma; or glaucoma associated with vascular disorders
* Corneal status as follows:

* Any active inflammation or edema
* Any pathology for which, in the investigator's judgement, the following would be either at risk or contraindicated:
* Implantation of Travoprost Intraocular Implant
* Compliance to elements of the study protocol (e.g., ophthalmic examinations, follow-up visits)
* Fellow eye status as follows:

* Fellow eye actively enrolled in this trial or any other clinical trial
* Subject status as follows:

* Pregnant or planning to become pregnant during the course of the study
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Glaukos Corporation

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Inland Eye Specialists

Hemet, California, United States

Site Status

North Bath Eye Associates, Inc.

Petaluma, California, United States

Site Status

Eye Center of northern Colorado, PC

Fort Collins, Colorado, United States

Site Status

The Eye Associates of Manatee

Manatee, Florida, United States

Site Status

Ocala Eye

Ocala, Florida, United States

Site Status

Center for Sight

Sarasota, Florida, United States

Site Status

Jones Eye Clinic

Sioux City, Iowa, United States

Site Status

D'Ambrosio Eye Care

Lancaster, Massachusetts, United States

Site Status

Northern New Jersey Eye Institute

South Orange, New Jersey, United States

Site Status

Oklahoma Eye Surgeons

Oklahoma City, Oklahoma, United States

Site Status

Vance Thompson Vision

Sioux Falls, South Dakota, United States

Site Status

Texan Eye

Austin, Texas, United States

Site Status

Lehmann Eye Center

Nacogdoches, Texas, United States

Site Status

Asian Eye Institute

Makati City, , Philippines

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Philippines

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IDOS-106-EXCH

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.